Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma
Public ClinicalTrials.gov record NCT00085189. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A PHASE II TRIAL OF A VACCINE COMBINING MULTIPLE CLASS I PEPTIDES WITH MONTANIDE ISA 51 OR ISA 51 VG AND CpG ADJUVANT 7909 FOR PATIENTS WITH RESECTED STAGES IIC/III AND IV MELANOMA
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This pilot phase II trial studies how well giving vaccine therapy works in treating patients with stage IIC-IV melanoma. Vaccines made from melanoma peptides or antigens may help the body build an effective immune response to kill tumor cells
Study identification
- NCT ID
- NCT00085189
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 42 participants
Conditions and interventions
Conditions
- Ciliary Body and Choroid Melanoma, Medium/Large Size
- Ciliary Body and Choroid Melanoma, Small Size
- Extraocular Extension Melanoma
- Iris Melanoma
- Metastatic Intraocular Melanoma
- Mucosal Melanoma
- Recurrent Intraocular Melanoma
- Recurrent Melanoma
- Stage IIC Melanoma
- Stage IIIA Intraocular Melanoma
- Stage IIIA Melanoma
- Stage IIIB Intraocular Melanoma
- Stage IIIB Melanoma
- Stage IIIC Intraocular Melanoma
- Stage IIIC Melanoma
- Stage IV Intraocular Melanoma
- Stage IV Melanoma
Interventions
- gp100 antigen Biological
- tyrosinase peptide Biological
- recombinant MAGE-3.1 antigen Biological
- multi-epitope melanoma peptide vaccine Biological
- incomplete Freund's adjuvant Biological
- Montanide ISA 51 VG Drug
- agatolimod sodium Drug
- laboratory biomarker analysis Other
Biological · Drug · Other
Eligibility (public fields only)
- Age range
- 16 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 2004 (Type not available)
- Primary completion
- Sep 2007 (Actual)
- Completion
- Sep 2007 (Actual)
- Last update posted
- May 22, 2014
2004 – 2007
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Southern California | Los Angeles | California | 90033-0804 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00085189, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 22, 2014 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00085189 live on ClinicalTrials.gov.